4basebio (XTER:88Q) Total Equity: €11.56 Mil (As of Dec. 2025)


XTER:88Q 4basebio PLC XTER:88Q
60 GF Score
Price €5.90
GF Value €30.95
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4basebio Total Equity?

4basebio XTER:88Q 60 Total Equity is €11.56 Mil as of Dec. 2025. GuruFocus rates XTER:88Q with a GF Score™ of 60/100 and a GF Value™ of €30.95 (Possible Value Trap). The stock has 7 warning signs investors should review.

4basebio's total equity for the quarter that ended in Dec. 2025 was €11.56 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

4basebio Total Equity Historical Data

* Premium members only.

The historical data trend for 4basebio's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4basebio Total Equity Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 13.76 8.19 -0.57 31.85 11.56

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -6.17 31.85 22.33 11.56
XTER:88Q
60GF Score
4basebio PLC XTER:88Q
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4basebio Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

4basebio's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=33.782-22.222
=11.56

4basebio's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=33.782-22.222
=11.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €11.56 Mil mean?
4basebio (XTER:88Q) has a Total Equity of €11.56 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for 4basebio and its competitors.
Is 4basebio's Total Equity too high?
4basebio's current Total Equity is €11.56 Mil. Overall, 4basebio has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4basebio's Total Equity compare to VRTX and REGN?
4basebio's Total Equity of €11.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for 4basebio and its competitors. 4basebio's current Total Equity is €11.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4basebio stock overvalued right now?
Based on GuruFocus' analysis, 4basebio (XTER:88Q) is currently considered Possible Value Trap. The stock's GF Value™ is €30.95, compared to a current price of €5.90 — trading 80.9% below its estimated fair value. The current Total Equity is €11.56 Mil. 4basebio's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For 4basebio (XTER:88Q), the current Total Equity is €11.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4basebio (XTER:88Q) Overvalued in 2026?

Based on GuruFocus' analysis, 4basebio stock appears to be undervalued. The current stock price of €5.90 is trading 80.9% below its estimated GF Value™ of €30.95. GuruFocus considers 4basebio to be Possible Value Trap.

Key valuation signals for XTER:88Q:

  • Total Equity: €11.56 Mil
  • GF Value™: €30.95 vs. price of €5.90 (80.9% below fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the XTER:88Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4basebio Business Description

Other Exchanges 4BB:UK
Address 25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
60GF Score

Get the complete analysis for XTER:88Q

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.90
Price
€30.95
GF Value